Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in CIDP
NCT04480450Phase 2Withdrawn
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2025
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of rituximab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by University of Kansas Medical Center. Planned start Jul 2025; status: withdrawn.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT04480450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480450.